Scientific Publications

Search by Keyword(s)
Found 4 results

Filters: Author is Scherer, CA  [Clear All Filters]

Search Results

  • Showing 1-4 of 4 Results
2014
Diversity-Oriented Synthesis probe targets Plasmodium falciparum cytochrome b ubiquinone reduction site and synergizes with oxidation site inhibitors.Lukens, AK, Heidebrecht RW Jr, Mulrooney C., Beaudoin JA, Comer E., Duvall JR, Fitzgerald ME, Masi D., Galinsky K., Scherer CA, Palmer M., Munoz B., Foley M., Schreiber SL, Wiegand RC, and Wirth DF The Journal of infectious diseases, 2014/10/21, (2014) Read More / View Supplemental Materials
Abstract
2012
A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.Weïwer, M., Spoonamore J., Wei J., Guichard B., Ross NT, Masson K., Silkworth W., Dandapani S., Palmer M., Scherer CA, Stern AM, Schreiber SL, and Munoz B. ACS medicinal chemistry letters, 2012/12/13, Volume 3, Issue 12, p.1034-1038, (2012) Read More / View Supplemental Materials
Abstract
Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.Wen, Q., Goldenson B., Silver SJ, Schenone M., Dancik V., Huang Z., Wang LZ, Lewis TA, An WF, Li X., Bray MA, Thiollier C., Diebold L., Gilles L., Vokes MS, Moore CB, Bliss-Moreau M., VerPlank L., Tolliday NJ, Mishra R., et al. Cell, 2012/08/03, Volume 150, Issue 3, p.575-89, (2012) Read More / View Supplemental Materials
Abstract
STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.Luo, T., Masson K., Jaffe JD, Silkworth W., Ross NT, Scherer CA, Scholl C., Fröhling S., Carr SA, Stern AM, Schreiber SL, and Golub T. R. Proceedings of the National Academy of Sciences of the United States of America, 2012/02/21, Volume 109, Issue 8, p.2860-5, (2012) Read More / View Supplemental Materials
Abstract
  • Showing 1-4 of 4 Results